KB-1105

Onartuzumab

Background

Onartuzumab is a recombinant, fully humanized, monovalent monoclonal antibody that binds the extracellular domain of MET, blocking interaction with HGF. This prevents activation of the MET signaling pathway, inhibiting the downstream events that lead to tumorigenesis. Onartuzumab was designed as a monovalent antibody because bivalent antibodies mimic HGF, stimulating MET signaling, whereas monovalent antibodies act as antagonists.

Specifications

Catalog Number:
KB-1105
Cell Line Name:
Onartuzumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
Met
Species Reactivity:
Human
Application:
ELISA | ELISA Blocking
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA | ELISA Blocking

References

1.Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A. 2013; 110: E2987–96. 2.Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12: 89–103. 3.Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992; 119: 629–41.
Please enable JavaScript in your browser to complete this form.